Form 4: BioLife Solutions CMO Sells Shares for Tax Obligations
Insider Transaction Report
BioLife Solutions' Chief Marketing Officer, Todd Berard, sold 344 shares of common stock to cover tax withholding obligations related to restricted stock vesting.
Summary
- Todd Berard, Chief Marketing Officer of BioLife Solutions Inc. (BLFS), reported a sale of common stock.
- The transaction involved 344 shares of common stock sold at a price of $25.59 per share.
- The total value of the shares sold was $8,799.96.
- The sale was executed on January 6, 2026, to satisfy tax withholding obligations related to the vesting of restricted stock.
- This transaction was conducted under a Rule 10b5-1(c) trading plan, which was adopted on January 3, 2023.
- Following this transaction, Mr. Berard beneficially owns 132,564 shares of BioLife Solutions common stock.
Sentiment
Score: 5
Explanation: The transaction is a routine, non-discretionary sale for tax withholding purposes under a pre-arranged 10b5-1 plan, which is generally considered neutral in terms of management's sentiment towards the company's prospects.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
This is a routine insider transaction, specifically a non-discretionary sale to cover tax obligations related to equity compensation. Such transactions are common across industries for executives receiving restricted stock units or similar equity awards and are generally not indicative of broader industry trends or company-specific operational performance.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Plan Disclosure | The sale was made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person effective as of January 3, 2023. This plan allows insiders to pre-arrange trades to avoid accusations of trading on material non-public information. | 01-03-2023 | Enhances transparency and provides an affirmative defense against insider trading allegations for pre-planned transactions. |
Stakeholder Impact
- Shareholders: Minimal direct impact as this is a small, non-discretionary sale for tax purposes, not indicative of a change in management's confidence.
- Employees: No direct impact mentioned.
Key Dates
| Date | Description |
|---|---|
| 01-03-2023 | Date Rule 10b5-1(c) trading plan was adopted by Todd Berard. |
| 01/06/2026 | Date of common stock transaction (sale). |
| 01/08/2026 | Date the Form 4 was signed and filed. |
Recommendation
holdThe reported transaction is a routine, non-discretionary sale by an officer to cover tax obligations associated with restricted stock vesting, executed under a pre-arranged Rule 10b5-1 plan. This type of insider sale is not typically indicative of a change in the officer's outlook on the company's future performance and therefore does not warrant a change in investment recommendation based solely on this filing. The stock should be held pending further operational or financial news.
Keywords
BioLife Solutions, BLFS, Form 4, insider transaction, stock sale, tax withholding, Rule 10b5-1, restricted stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.